Twist1, a basic helix-loop-helix transcription factor is implicated as a key mediator of epithelial-mesenchymal transition (EMT) and metastatic dissemination in p53-deficient cancer cells. On the other hand, checkpoint kinase 2 (Chk2), a major cell cycle regulatory protein provides a barrier to tumorigenesis due to DNA damage response by preserving genomic stability of the cells. Here we demonstrate that Chk2 induction proficiently abrogates invasion, cell scattering and invadopodia formation ability of p53-mutated invasive cells by suppressing Twist1, indicating Chk2 confers vital role in metastasis prevention. In addition, ectopic Chk2, as well as its (Chk2) induction by natural podophyllotoxin analog, 4′-demethyl-deoxypodophyllotoxin glucoside (4DPG), strongly restrain Twist1 activity along with other mesenchymal markers, for example, ZEB-1, vimentin and Snail1, whereas the epithelial markers such as E-cadherin and TIMP-1 expression augmented robustly. However, downregulation of endogenous Chk2 by siRNA as well as Chk2 selective inhibitor PV1019 implies that 4DPG-mediated inhibition of Twist1 is Chk2-dependent. Further, mechanistic studies unveil that Chk2 negatively regulates Twist1 promoter activity and it (Chk2) interacts steadily with Snail1 protein to curb EMT. Strikingly, Chk2 overexpression triggers premature senescence in these cells with distinctive increase in senescence-associated β-galactosidase (SA-β-gal) activity, G2/M cell cycle arrest and induction of senescence-specific marker p21 waf1/Cip1 . Importantly, stable knockdown of Twist1 by shRNA markedly augments p21 expression, its nuclear accumulation, senescence-associated heterochromatin foci (SAHF) and amplifies the number of SA-β-gal-positive cells. Moreover, our in vivo studies also validate that 4DPG treatment significantly abrogates tumor growth as well as metastatic lung nodules formation by elevating the level of phospho-Chk2, Chk2 and suppressing Twist1 activity in mouse mammary carcinoma model. In a nutshell, this report conceives a novel strategy of Twist1 suppression through Chk2 induction, which prevents metastatic dissemination and promotes premature senescence in p53-defective invasive cancer cells.
Epithelial-mesenchymal transition (EMT), a key biological process is manifested during development by which epithelial cells acquire mesenchymal, fibroblast-like phenotype and predominantly exhibit reduced intercellular adhesion. 1, 2 In cancer, EMT plays a critical role in imparting more aggressive behavior to the cells for metastatic spread of the disease. 1 Twist1, a basic helix-loop-helix transcription factor is overexpressed during the process in various carcinomas, sarcomas, neuroblastomas, gliomas and melanomas. 3, 4 At the molecular level, Twist1 facilitates MDM2-mediated degradation of p53, renders the cancer cells more aggressive and resistant to therapies. Hence, high levels of Twist1 expression is a predominant feature in p53-defective cancer cells. 5, 6 Twist1 downregulates epithelial markers such as E-cadherin, TIMP1 and augments the mesenchymal markers namely, Vimentin, ZEB-1, MMP-2 and N-cadherin driving the cells toward malignancy. 3, 4 Twist1 has been demonstrated to suppress p21 at the promoter level; thus preventing the cells from undergoing senescence and activates EMT program. 7 Hence, regulating Twist1 activity to prevent aberrant invasive signaling and to turn on senescence machinery could divulge new therapeutic strategies.
Chk2 is a key tumor suppressor of the DNA damage checkpoint pathway, which is activated in response to exogenous insults including ionizing radiation and chemotherapeutics. 8 DNA double-strand breaks (DSBs) stimulate ataxia-telangiectasia-mutated (ATM) protein kinase that subsequently phosphorylates Chk2 at Thr68 and activates it. 9 However, hyperactive Chk2, in turn, directly phosphorylates and regulates the downstream functions of p53, CDC25 and BRCA1 implying checkpoint activation and G2/M cell cycle arrest. 10 Emerging evidence demonstrates that Chk2 kinase significantly contributes in inducing both replicative and premature cellular senescence. 11, 12 High level of virally transduced Chk2 in human lung cancer A549 cells leads to transcriptional induction of p21, activation of p53, G2/ M cell cycle arrest and senescence. 13 However, Chk2-dependent senescence and transcriptional induction deeply corroborate in p53-defective SK-BR-3 (breast carcinoma) and HaCaT (immortalized keratinocyte) cells, suggesting a p53-independent role of Chk2 in p21 induction and senescence. 13 Albeit, the functions of Chk2 in DNA damage response and cell cycle regulation is well documented, how it regulates excessive oncogenic signaling leading to invasion and metastasis and favors cellular senescence as a protective mechanism, is yet to be studied.
This report for the first time describes a functional role of Chk2 induction by ectopic overexpression as well as by treatment with (4′-demethyl-deoxypodophyllotoxin glucoside (4DPG) attenuating Twist1-mediated invasion and metastasis in p53-defective cancer cells from diverse tissue origin. Furthermore, this Chk2-mediated rescuing of p21 to promote premature senescence as a tumor suppressive safeguard mechanism in these cells warrants a novel strategy for pharmacological intervention.
Results

Chk2 overexpression abrogates motility/invasion of cancer cells and regulates the EMT-related markers.
Mutations in p53 tumor suppressor gene directly contributes to EMT by regulating the expression of some metastasisrelated genes. 14 We examined the effect of Chk2 overexpression on the invasion of three p53-defective aggressive cancer cell lines namely, MDA-MB-231, DU 145 and PANC-1. Figure S1a) . We also performed the same experiment on p53 null human prostate cancer PC-3 cells. Our results demonstrated that Chk2 expression strongly impeded the invasion of aggressive PC-3 cells (Supplementary Figure S1b) . Invadopodia formation is an important platform to study the EMT process, 15 and therefore we examined the effects of GFP-Chk2 on the invadopodia formation ability of MDA-MB-231 and DU 145 cells. The results implied sufficient degradation of FITCgelatin matrix in GFP-transfected cells, the degradation ability was significantly reduced in cells transfected with GFP-Chk2 (Figures 1c and d) . Furthermore, GFP-transfected cells scattered out of the colonies upon stimulation with bFGF; whereas, GFP-Chk2 convincingly halted the bFGF-induced cell migration (Figures 1e, f and Supplementary Figure S1c) .
Since Chk2 overexpressed cells displayed retarded invasion ability, we sought to examine the major mesenchymal markers of EMT and invasion in these cells. Recombinant fused GFP-Chk2 expression was adequate along with a phospho-T68 signal indicating an optimum threshold activation of the recombinant protein. 16 Further, the immunoblot results indicated a steady-state downregulation of Twist1 with concomitant decrease in Snail1, MMP-2, vimentin protein levels and upregulation of epithelial markers such as E-cadherin and TIMP-1 in GFP-Chk2-transfected cells compared to the GFP (Figure 1g and Supplementary Figure S1d ). In addition, the immunofluorescence analysis illustrated a marked reduction of Twist1 in Chk2 overexpressing cells compared to the vector-transfected cells (Figure 1h ).
These results collectively establish Chk2 induction abrogates EMT in p53-defective invasive cancer cells.
Chk2 activation by 4DPG negatively regulates Twist1-mediated invasion in cancer cells. 4DPG, a novel natural podophyllotoxin congener, has recently been reported by our group for its promising anticancer activities in diverse cancer cell lines (Figure 2a) . 17 The cytotoxicity results indicated that 4DPG effectively inhibited the proliferation of MDA-MB-231, PANC-1 and DU 145 cells with IC 50 values of 0.256 ± 0.062, 0.272 ± 0.049 and 0.281 ± 0.035 μM, respectively, whereas the IC 50 value of 4DPG in normal human breast epithelial (fR2) cells was found to be 24.5 ± 5.125, signifying the selectivity of the molecule toward cancer cells (Supplementary Figure S2 and Supplementary Table S1 ). To initiate a detailed investigation of the effects of 4DPG on Chk2 activity, we performed concentration-dependent western blot analysis. Although the results unveiled a robust upregulation of pChk2 (T68) as well as total Chk2 at the 200 and 300 nM doses of 4DPG, a substantial p-Chk2 induction was visible even at the initial concentration (100 nM) for all the three cell lines tested (Figure 2b ). Further, timedependent experimental data demonstrated a shoot-up in the expression of pChk2 and total Chk2 even at the 12 h, which gradually augmented to the 48 h (Figure 2c ). To further confirm, whether the compound exclusively upregulates Chk2 expression, we conducted western blot analysis for Chk1. The results showed unaltered expression of Chk1 in these cells even at the higher concentration ( Supplementary  Figures S3a and b) . Furthermore, our matrigel invasion assay results in MDA-MB-231 and DU 145 cells unveiled a sufficient reduction in the number of invading cells in 4DPG (300 nM)-treated wells compared to the untreated control (Figures 2d  and e) . We also observed a remarkable reduction in the area of degradation over the FITC-gelatin matrix, indicating a significant loss of invasive potential in 4DPG (300 nM)-treated cells (Figures 2f and g ). 4DPG treatment also abrogated the growth factor-induced scattering of highly invasive mouse mammary carcinoma (4T1) cells (Supplementary Figure S4) . Rationally, we investigated whether 4DPG could modulate the expression of mesenchymal/epithelial markers to suppress the invasion of p53-defective aggressive cells; as expected, the immunoblot data revealed a significant downregulation of Twist1, Snail1, ZEB-1, vimentin and MMP-2 expression with concomitant increase in epithelial markers E-cadherin and TIMP-1 in presence of 4DPG (Figures 2h  and i) . The immunocytochemistry data also demonstrated a significant decrease in Twist1 level in cells treated with 4DPG (300 nM) for 48 h (Figure 2j ). Taken together, these results imply that 4DPG suppresses invasion of p53-deficient metastatic cancer cells via activation of Chk2.
Inhibition of Chk2 augments Twist1-mediated EMT and invasion. Next, we were curious to examine whether silencing of endogenous Chk2 could revert the invasiveness of cancer cells. In order to do this, siRNA-mediated silencing of endogenous Chk2 was carried out in MDA-MB-231cells following subjected to matrigel invasion assay. Indeed, the results depicted a significant increase in cells invading through the matrigel in siChk2-transfected cells compared PV1019 treatments) with a simultaneous decrease in E-cadherin expression in the corresponding lanes. On the other hand, 4DPG treatment significantly amplified the Chk2 levels in the scramble plus 4DPG and 4DPG treatment cells, respectively (Figure 3c) . The immunocytochemistry data also demonstrated a robust increase in Twist1 expression when Chk2 was partially knocked down through siRNA transfection as well as PV1019 treatment compared to scramble/vehicle treatment (Figure 3d ). To examine the cellular morphology, we used TGF-β as an inducer of EMT and noted that PANC-1 cells treated with TGF-β (10 ng/ml) for 24 h exhibited prominent mesenchymal phenotypes. Conversely, Chk2 overexpression with HA-Chk2 or treatment with 4DPG (300 nM) reverted this mesenchymal morphology in these cells compared to vector or untreated control (Supplementary Figure S6) . All these results clearly demonstrate that 4DPG-mediated Twist1 inhibition was Chk2-dependent. , p19
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. 13, 19 Intriguingly, GFP-Chk2 expression showed elevated expression of senescencespecific marker p21 with concomitant induction of p16, p19 as well as diminished expression of CDK2 and cyclin D1 within 72 h of transfection (Figures 4d and e) . Although premature senescence is associated with inhibition of cell proliferation per se 20 we noted that GFP-Chk2 significantly hindered the colony-forming ability of all the three cancer cell lines (Supplementary Figure S7) . To determine the effect of 4DPG, a potential agonist of Chk2, on cell cycle, we performed bromo-deoxyuridine (BrdU) incorporation assay in MDA-MB-231 cells. Interestingly, we found an increase in G2/ M population of the BrdU-positive cells ( Figures S8a and b) . Furthermore, analysis of downstream effectors of Chk2 function demonstrated a marked increase in p21 expression accompanied with p19 and deceleration in CDK2 level in a dose-dependent manner (Supplementary Figure S8c) . Our immunocytochemistry results also depicted that 4DPG (300 nM) was able to induce nuclear accumulation of p21 in MDA-MB-231, PANC-1 and DU 145 cells (Figure 4h ). It is reported that Chk2 can activate senescence by inducing p21 in p53 intact cells. 13 Supporting, our results revealed that GFP-Chk2-transfected MCF7 cells undergone premature senescence forcibly compared to their respective GFP control cells. However, in TGF-β-treated wells, EMT features become predominated ( Supplementary Figures S9a and b) .Together, these results show that Chk2 activation mimics the induction of checkpoint response to DNA damage, activating the p53-independent p21pathway to promote senescence.
Chk2 activation negatively regulates Twist1 promoter activity and it (Chk2) interacts with Snail1. So far, our results clearly pointed out that Chk2 induction was consistently modulating the major EMT regulator Twist1; therefore, we hypothesized that Chk2 could regulate Twist1 promoter activity and blocked the formation of Twist1 mRNA. As expected, the quantification real-time reverse transcription-PCR results implied a sharp attenuation in Twist1 mRNA level in cells transfected with GFP-Chk2 (2.5-fold in MDA-MB-231 and 2.6 fold in DU 145) (Figure 5a ), whereas the E-cadherin mRNA level augmented markedly (15- Figures S10a and b) . To further determine whether Chk2 regulates Twist1 transcription, we analyzed Twist1 promoter activity through a Dual-Glo Luciferase Assay System (Promega). Notably, the results demonstrated that the relative luciferase activity of cells co-transfected with Twist-Luc and GFP-Chk2 reduced significantly (6.2-fold in MDA-MB-231 and 8.5-fold in DU 145) compared to the cells co-transfected with Twist-Luc and GFP, indicating a negative regulation of Twist1 promoter activity by Chk2 (Figures 5c and d) . However, co-transfection of a kinase-dead Chk2 (hChk2-D347A) along with Twist-Luc could not suppress the Twist1 promoter activity in these cells. Conversely, the Twist-Luc activity augmented in siChk2-transfected as well as PV1019-treated cells (Figures 5c and d) . Furthermore, when subjected to 4DPG (300 nM), the luciferase activity of Twist1 reduced convincingly (3-fold in MDA-MB-231 and 2.3-fold in DU 145) compared to the vehicle (Supplementary Figures  S11a and b) . For comprehensive understanding of the molecular mechanism by which Chk2 negatively regulated Twist1 transcriptional activity and protein expression, we were in hunch of upstream regulators that activate Twist1-mediated EMT and invasion. Snail1, a zinc-finger E-boxbinding protein initiates EMT programme by repressing epithelial genes such as E-cadherin by binding to its promoter. 1 We were curious to investigate whether any physical interaction exist in between Chk2 and Snail1 to regulate EMT in p53-defective cancer cells. Interestingly, our coimmunoprecipitation analysis demonstrated that Snail1 antibody coimmunoprecipitated Chk2 in GFP-Chk2 stable clone of DU 145 cells; similarly Chk2 antibody, but not the control antibody coimmunoprecipitated Snail1 in these cells (Figure 5e ). All these results collectively suggest that Chk2 regulates Twist1 at the transcriptional level by suppressing its (Twist1) promoter activity and Chk2 interacts with Snail1 protein in p53-deficient cancer cells.
Stable knockdown of Twist1 promotes premature senescence through induction of p21. Twist1 has been previously documented to halt premature senescence by suppressing p21 at the transcriptional level by directly binding to its promoter in a p53-independent manner. 21 To examine, whether stable knockdown of Twist1 can avert EMT through inducing senescence by rescuing p21, we prepared stable Twist1 knockdown clones of MDA-MB-231, DU 145 and PANC-1 cells employing Twist1 shRNA. Our SA-β-gal staining of the shTwist1 clones implicated a marked boost in SA-β-gal-positive staining (46% in MDA-MB-231, 55% in PANC-1 and 48% in DU 145) compared to the scrambletransfected clones (Figures 6a and b) . We also observed an increase in SAHF in the shTwist1 stable clones of MDA-MB-231, PANC-1 and DU 145 compared to the scramble (Figure 6c ). Our immunoblotting and immunocytochemistry experiments further validated a significant upregulation of p21 (8.5-fold in MDA-MB-231, 4.2-fold in PANC-1 and 3.9-fold in DU 145) in shTwist1 stable clones with concomitant reduction of Twist1, CDK2, ZEB-1 and MMP-2 expressions along with the increase in Chk2 expression (Figures 6d  and e) . DDR stimulates ATM protein kinase, which in turn phosphorylates Chk2 (T68) for its activation. 9 The same ATM kinase also stabilizes Snail1 by phosphorylating it on S100, and thus instigating in tumor invasion and metastasis. 22 Hence, there might be some orchestration of feedback loop interplaying through downstream effectors like Twist1 affecting Chk2 activity through this axis. Our immunocytochemistry results also confirmed a steady nuclear accumulation of p21 in shTwist1 stable clones in comparison to the scramble in these cells (Figure 6f and Supplementary Figure S12) . Collectively, these results provide evidences that suppression Figure 5 Chk2 negatively regulates transcriptional activity of Twist1 and it (Chk2) binds to Snail1. (a and b) MDA-MB-231 and DU 145 cells were transiently transfected with GFP and GFP-Chk2 construct for 48 h and checked for the mRNA level of Twist1 and E-cadherin through real-time PCR analysis. β-actin gene was used as an internal control for normalization (n = 3, error bars indicate ± S.D.). **Po0.01. (c and d) MDA-MB-231 and DU 145 cells were transfected with Twist-Luc promoter and co-transfected with Twist-Luc plus GFP, Twist-Luc plus GFP-Chk2, Twist-Luc plus Chk2-D347A, Twist-Luc plus scramble siRNA, Twist-Luc plus siChk2 and/or treated with Twist-Luc plus vehicle as well as Twist-Luc plus PV1019 for 48 h. Luciferase activity was measured with the help of a Dual-Glo Luciferase assay system (Promega). Normalization was done with luciferase activity of PGL3 vector (n = 3, error bars indicate ± S.D.). **Po0.01. (e) Activated Chk2 binds to endogenous Snail1 in p53-deficient cancer cells. Whole-cell extracts of Chk2-DU 145 stable cells were prepared and subjected to immunoprecipitation with Chk2 antibody, Snail1 antibody and control antibody. The immunoprecipitates and inputs were subjected to western blot analysis for Chk2 and Snail1 expression
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In vivo tumor growth and metastasis study. To evaluate the effect of cellular Chk2 inducer 4DPG on tumor growth and metastases in vivo, we employed 4T1 mouse mammary carcinoma model. The primary tumors showed 86% inhibition in tumor volume in the 4DPG-treated group compared to the normal saline (Figures 7a and b) . Interestingly, a series of metastatic lung nodules (yellowish-white patches) were observed spreading over the lungs in control animals, whereas lungs dissected from the animals treated with 4DPG were mostly devoid of metastatic lesions indicating abrogation of lung metastases from the mammary pads (Figures 7c and d) . Isolation of the 4T1 cells from the lung suspension further depicted a large number of colonies in the flask containing the lung suspension from saline-treated animals, whereas, a few colonies were identified in the 4DPG-treated group, confirming the loss of metastatic ability of 4T1 cells from the primary tumor following exposure to 4DPG (Figures 7e and f) . The immunohistochemistry results revealed a marked increase in pChk2 and Chk2 along with diminish Twist1 expression in tumors dissected from 4DPG-treated group compared to the vehicle treatment (Figure 7g ). Together, these data strongly imply that 4DPG is a potential inhibitor of tumor growth and metastases.
Discussion
In this report, we conceive Chk2 as a major target to curb EMT in p53-defective aggressive cancer cells by its (Chk2) ectopic overexpression or exposure to natural product 4DPG. In a broader sense, the active Chk2 not only halt/reduce EMT but more precisely turn on senescence cascade in these cancer cells. Therefore, novelty of this study does not limit the circumference of the therapeutic usage of 4DPG through opening up new avenues of treatment regime in metastatic cancer cells. Interestingly, this study underscores that Chk2 activation is an essential prerequisite for the abrogation of invasion in cancer cells by Chk2-mediated transcriptional repression of Twist1 and stable knockdown of Twist1 promotes senescence in these p53-defective cells (Figure 8 ). In response to oncogenic stimuli, nuclear factor-kB (NF-kB), a transcription factor positively regulates transcription of major mesenchymal genes including Snail1 and Twist1 to further aggravate the disease. 23, 24 NF-kB (p65) is crucial for TNF-α-induced expression of Twist1 through a canonical signaling. 24 However, a study by Solanas et al. 25 demonstrates that overexpression of Snail1 can upregulate transcriptional activity of NF-kB in SW-480 and MiaPaca-2 cells, providing evidences that there might be existing some feedback mechanism behind this regulation. Keeping in mind, the above crosstalk between Snail1 and NF-kB in activating Twist1, we hypothesized that Chk2 can interact with Snail1 to affect Twist1 transcriptional activity via NF-kB. Indeed, our coimmunoprecipitation analysis implies that in stably expressing Chk2-DU 145 cells, Chk2 binds to Snail1 through proteinprotein interaction. Here, for the first time, we report a novel interaction between Chk2 and Snail1 in the regulation of Twist1-mediated EMT and invasiveness in p53-defective cancer cells.
Senescence could be triggered by diverse stress signals, including DNA damage responses, irrespective of the p53 status of the cell. 13 Supporting the evidence, GFP-Chk2 overexpression/4DPG treatment of three different p53-defective aggressive cancer cells consistently augmented Figure 8 Schematic representation of the proposed mechanism of action of Chk2 in metastasis prevention and induction of senescence. Chk2 induction inhibits EMT through suppression of matrigel invasion, cell scattering and invadopodia-formation ability of invasive p53-defective cancer cells. At the molecular level, Chk2 inhibits Twist1 transcriptional activity, thereby, negatively regulating pro-EMT markers such as Snail1, ZEB-1, vimentin, MMP-2 and favoring anti-EMT markers such as E-cadherin and TIMP-1. This role of Chk2 further activates premature senescence with a decrease in cell proliferation, G2/M cell cycle arrest and increase in SA-β-gal activity in these cells coupled with induction of senescence-specific marker p21 expression along with p16, p19 and downregulation of CDK2 and cyclin D1 expression
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Debasis Nayak et al robust nuclear accumulation of p21, increasing p16, p19 and decelerated CDK2 levels to promote senescence. A recent study by Galanos et al. 26 demonstrates that in p53 mutant human cancers, sustained p21 accumulation inhibit ubiqutin ligases CRL4-CDT2 leading to deregulated origin licensing, genomic instability and aggressiveness. Studies also demonstrate that the oncogenic function of p21 is attributed to unconventional cytoplasmic localization of p21 that inactivates pro-apoptotic proteins. 27 However, the present study focuses on the activation of Chk2 repressing the transcriptional activity of Twist1 through its binding to Snail1, thus preventing invasion. In addition, Chk2 also induces premature senescence in these cells by neutralizing the inhibitory effect of Twist1 on p21 expression. Moreover, stably expressing Chk2-DU 145 cells showed sufficient senescent phenotypes with increase in SA-β-gal activity and p21 expression indicating, Chk2 activation promotes and maintains senescence in these aggressive cells (Supplementary Figures S13a-c) .
Senescence is a complex biological process that hinders incipient cancer cells from acquiring the malignant transformation. 12 Since p53 is a whistleblower to determine the fate of the victimized cell whether to opt for apoptosis or senescence; recent evidence suggest that senescence gets priority to rescue from such catastrophic condition in the p53-defective background. 12 In those consequences, Chk2 would be an appropriate target to restore cellular senescence, since chemotherapies are most likely to be efficacious in those tumors that senesce compared to those that do not. [28] [29] [30] 4DPG, an aryltetralin-type lignan was first isolated from Podophyllum emodi 31 and showed remarkable potency (15-fold more potent than its natural congener 4′-demethyldeoxypodophyllotoxin). 17 In the present study, we report 4DPG is a potent inducer of cellular Chk2, not Chk1 and targeting Chk2-mediated anti-tumor and anti-metastatic approach would be promising leap for the development of next-generation phytomedicine.
Materials and Methods
Cell culture. All the cell lines used in this study were procured from American Type Culture Collection (ATCC, Manassas, VA, USA). The p53 status of the cell lines (i.e., MDA-MB-231: p53 R280K, DU 145: p53 P223L, PANC-1: p53 R273H, PC-3: p53 null, 4T1: p53 null, MCF7: p53 intact) were confirmed from p53 database of the TP53 website. MDA-MB-231 cells were cultured in Leibovitz's L-15 medium, DU 145, MCF7 cells in RPMI-1640 medium and PANC-1 cells in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA) and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA) in a humidified CO 2 incubator (New Brunswick Galaxy 170 R) with 5% CO 2 . Mouse mammary carcinoma 4T1 cells (a gift from Dr Avinash Bajaj, Regional Center for Biotechnology, New Delhi, India) were cultured in the RPMI-1640 medium.
Matrigel invasion assay. The cell invasion through matrigel was carried out with the BD Biocoat Tumor Invasion Assay System (BD Biosciences, Bedford, MA, USA) according to the manufacturer's instruction and described previously. 32 In situ fluorescent gelatin degradation assay. The matrix gelatin degradation assay was performed to assess the formation of invadopodia or podosomes. Following transfection of the MDA-MB-231 and DU 145 cells with GFP and GFP-Chk2 plasmid or 4DPG treatment was analyzed by fluorescence microscope according to the method previously described. 32 Cell scattering assay and clonogenic assay. The cell scattering and colony formation were determined according to the earlier described experimental protocol. 32 For cell scattering, bFGF (20 ng/ml) was employed to stimulate cell motility. A total of five random colonies from each field were analyzed and counted manually under the microscope for the number of scattered cells and was adjusted to the total cells in particular colony.
Transient transfection. MDA-MB-231, DU 145, PANC-1 and PC-3 cells were harvested and transfected with GFP and GFP-Chk2, pCDNA3 and HA-Chk2 plasmid construct (generously gifted by Dr. Domenico Delia, Fondazione IRCCS Istituto Nazionale Tumori, Italy); hChk2-D347A (kindly gifted by Ann C. Tuma, Jann Sarkaria's Laboratory, Mayo Clinic, Rochester, MN, USA); using Neon Transfection System (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction.
siRNA knockdown experiments. MISSION esiRNAs for human CHEK2 (EHU158481), were procured from Sigma-Aldrich (St. Louis, MO, USA) and transfection experiments were performed using oligofectamine (Life Technologies, Carlsberg, CA, USA) according to the manufacturer's instructions.
Cell viability assay. The cell viability was assessed in the presence of 4DPG by standard MTT dye uptake method according to the procedure previously described. 33 SA-β-gal staining and SAHF detection. The procedure was followed as described previously. 34 Briefly, cells (0.4 × 10 6 ) were seeded in six-well plates and transfected with GFP, GFP-Chk2 or treated with vehicle and 4DPG (300 nM) for 72 h. Cells were accordingly washed twice with PBS, fixed with 4% paraformaldehyde for 5 min, rinsed twice with PBS and incubated with freshly prepared staining solution (40 mM citric acid/Na phosphate buffer, 5 mM K 4 6 ], 150 mM sodium chloride, 2 mM magnesium chloride and 1 mg/ml X-gal in distilled water, pH 6.0) for 48 h at 37°C. Successively, stained cells were thoroughly washed and air dried in dark. Cells were then observed under bright-field microscope (NIKON, Nikon Corporation, Chiyoda-ku, Tokyo, Japan) for the SA-β-gal-positive cells and images were captured at × 20 magnification.
The senescence-associated heterochromatin foci (SAHF) detection method was carried out as per the previously described method. 18, 35 On the previous day, about 20 000 MDA-MB-231, DU 145 cells were seeded in eight-well chamber slide following transfection with GFP and GFP-Chk2 or 4DPG treatment (next day). After 10 days, the cells were washed with PBS and fixed with 4 % paraformaldehyde (w/v) at room temperature for 10 min. After discarding the paraformaldehyde, cells were washed with PBS, stained and mounted with UltraCruz mounting media containing DAPI (Invitrogen). Fluorescence images were captured with Floid cell imaging station (Invitrogen) using × 20 objective.
BrdU cell proliferation assay. Briefly, MDA-MB 231 cells were seeded at 0.3 × 10 6 cells per well on 35-mm Petri dishes and incubated for overnight. Next day, the medium was changed and cells were treated with vehicle and 4DPG (300 nM) for 72 h. The cells were pulse labeled with 30 μM BrdU (Sigma) for 1 h in the dark prior to harvesting. Cells were then trypsinized, centrifuged at 2000 r.p.m. for 3 min, washed twice in ice-cold PBS containing 1% BSA and fixed with ice-cold 70% ethanol (v/v) for 2 h at 1°C. Cells were then washed twice with PBS and resuspended in denaturing buffer (2 N HCl/0.5%Triton X-100) to expose labeled DNA for an additional 30 min at room temperature. After denaturation, cells were pelleted and washed with PBS/1% BSA containing 0.1% Triton X-100. Cells were then treated with 0.1 M sodium borate buffer (pH 8.5) for 2 min at room temperature to neutralize the acid and washed out. The pellet was washed twice with PBS/1% BSA containing 0.1% Triton X-100 and the cells were stained with fluorescein isothiocyanate (FITC)-conjugated anti-BrdU antibody (Thermo Fisher Scientific, Boston, MA, USA) in 0.5% Tween 20/1% BSA/PBS for 1 h at 37°C in dark. Cells were washed twice with PBS/1% BSA and resuspended in PBS containing RNAse A (200 μg/ml) and propidium iodide (PI) (50 μg/ml) in dark prior to flow cytometry. Cells were acquired with Gallios 10-color flow cytometer (Beckman Coulter Inc., Fullerton, CA, USA) and data were analyzed using Kaluza analysis software (Beckman Coulter, version 1.3).
Flow cytometric cell cycle analysis. MDA-MB-231 and DU 145 cells were seeded at 0.3 × 10 6 cells per well on 35-mm dishes and incubated for overnight at 37°C and 5% CO 2 . Next day, the cells were treated with vehicle and 4DPG (300 nM) for 72 h. After the completion of the incubation period, adherent cells were trypsinized, centrifuged at 2000 rpm for 3 min, washed twice with ice-cold Inhibition of Twist1-mediated invasion by Chk2 Debasis Nayak et al PBS and fixed with ice-cold 70% ethanol (v/v) for 1 h at 4°C. Cells were washed with PBS and incubated with 50 μg/ml of PI and 200 μg/ml of RNase A in PBS at room temperature for 30 min in dark. Acquisition was performed on Gallios 10-color flow cytometer (Beckman Coulter Inc.) and data were analyzed using Kaluza analysis software (Beckman Coulter, version 1.3).
Western blotting. Western blot analysis was carried out as per the indicated condition (figure legends) as previously described. 33 The list of antibodies and their working dilutions are described in Supplementary Table S2 .
Immunofluorescent staining. MDA-MB-231, PANC-1 and DU 145 cells were seeded in eight-well chamber slide at a density of 0.5 × 10 5 cells per well. These cells were further treated as per the indicated condition (figure legends). Successively, immunocytochemical studies were carried out following the published protocol. 36 The antibodies used and their working dilutions were provided in Supplementary Table S2 . Images were captured under Floid Cell Imaging Station (Invitrogen) at × 20 magnification.
RNA extraction and quantitative real-time PCR. Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Life Technologies) according to the manufacturer's protocol. A total of 5 μg of RNA was treated with DNase (Ambion TURBO DNA-free, Life Technologies). First-strand cDNA synthesis was carried out using the ImProm-II Reverse Transcription System (Promega, Madison, WI, USA) according to the manufacturer's instructions, with an anchored oligo-dT 12 primer (FirstChoice RLM-RACE Kit, Ambion, Life Technologies) and 1 μg of DNase-treated RNA as a template. Gene-specific primers used for quantitative real-time RT-PCR (qPCR) study was designed using LightCycler Probe Design Software 2.0 (Hoffmann-La Roche, Basel, Switzerland). Primer details are mentioned in Supplementary Table S3 . Primers were verified using conventional endpoint PCR for single-band amplification.
The real-time quantitative PCR assay was carried out using the LightCycler 96 Real-Time PCR System (Hoffmann-La Roche). Each PCR reaction (10 μl) contained 1 × LightCycler 480 SYBR Green I Master (Hoffmann-La Roche), 1 μM primers (Integrated DNA Technologies, Coralville, IA, USA) and cDNA (appropriately diluted). Thermal cycling conditions for the qPCR were as follows: pre-incubation at 95°C for 10 min, followed by 50 cycles of three-step amplification (95°C for 10 s, 55°C for 15 s and 72°C for 15 s). The PCR was followed by a dissociation curve analysis (heating to 95°C for 10 s at normal ramping, cooling to 65°C for 60 s at normal ramping followed by slow heating to 97°C for 1 s at a reduced ramping rate of 0.2°C/ s) to ensure qPCR reaction specificity. Each assay was carried out in triplicate, and a non-template negative control was included. β-actin gene was chosen as a housekeeping, internal control for normalization. The threshold cycle (C t ) of the amplification curve was used for the calculations. The relative expression level was analyzed using the 2 − ΔΔCt method, 37 where -ΔΔ Ct = (C t, target − C t, actin ) time x − (C t, target − C t, actin ) time 0 .
Preparation of stable cell lines. Stable Twist1 short-hairpin RNA or scramble transfected clones were prepared by transfecting the cells with MISSION shRNA for Twist1 (CCGGAGTCCGCAGTCTTACGAGGAGCTCGAGCTCCTCGTA AGACTGCGGACTTTTTTG) (Sigma) through electroporation by Neon Transfection system (Invitrogen). Clones were selected by periodic treatment of puromycin to the cells for 15 days, then pooled and tested for the Twist1 expression through confocal microscopy as well as western blot analysis. Stable GFP and GFP-Chk2-transfected clones were prepared by transfecting DU 145 cells with Lipofectamine 2000 (Invitrogen) as per the manufacturer's instruction. Clones were selected by periodic treatment of geneticin (G418) (Sigma-Aldrich) to the cells for 15 days. Clones were then pooled and tested for the Chk2 ectopic expression through confocal microscopy and western blotting.
Luciferase reporter assay. We employed Twist1 promoter containing genes for luciferase activity (Twist-Luc) of +1 to − 824 bp in a PGL3-Luc vector generously gifted by Dr. Mien-Chie Hung (MD Anderson Cancer Center, The University of Texas, USA). The promoter region contains a TATAA box at nt − 32 to − 28 bp, relative to the transcription start site. The proximal promoter region contains two putative STAT3-binding elements and the critical NF-kB (p65) DNA-binding elements are located at the 120-bp region of the promoter. 24, 38 MDA-MB-231 and DU 145 cells were transfected with Twist-Luc and incubated overnight in 96-well tissue culture plates at 10 × 10 3 cells per well. Cells were then either co-transfected with either GFP, GFP-Chk2, Chk2-D347A, scramble, siChk2 and treated with vehicle, PV1019 and/or 4DPG for 48 h. The luciferase activity was measured with the help of a Dual-Glo Luciferase assay system (Promega) according to the manufacturer's protocol. Normalization was done with the luciferase activity of PGL3 vector in each condition.
Coimmunoprecipitation analysis. The procedure was followed as previously described with minor modifications. 39 Briefly, stable clones of GFP and GFP-Chk2-transfected DU 145 cells (2 × 10 6 each) were cultured in 90 mm Petri dishes in a humidified CO 2 incubator for 24 h. Cells were then harvested with cell scrapper, washed with PBS and resuspended in lysis buffer (containing 1 × PBS (pH 7.5), 1% Triton X-100, 0.1% SDS, 5 mM EDTA, 1 mM PMSF, 1% NP-40, 100 μM Na 3 VO4and 1 × protease inhibitor cocktail from Roche, Inc. (Roche, Basel, Switzerland)), centrifuged at 14 000 r.p.m. for 10 min to remove cell debris, and precleared by adding 50 μg of protein G PLUS-Agarose beads. Precleared lysates were subjected to immunoprecipitation with 5 μg of antibody conjugated to 50 μl of protein G PLUS-Agarose beads. The immunoprecipitates were washed with lysis buffer and employed for western blot analysis.
Experimental animals. All animals used in this study were bred and maintained at the central animal facility of Indian Institute of Integrative Medicine, Jammu, India. Animals were maintained at 20-25°C in a 12 h light-dark cycle, routinely monitored for their diet and water consumption and proper sanitations were maintained to avoid any risk of possible pathogenic contamination. Animal studies were performed in accordance with the experimental guidelines that were approved by the Animal Ethics Committee of the institute 'CPCSEA' (IAEC No. 51/02/15). During the animal experiments, special handling and care were adopted in a humane way, so that no extra pains/injuries were imparted to the animals. To minimize the mortality of animals during experimentation, only a limited number of animals were employed to yield the statistically significant results.
Mouse model for tumor growth and metastasis. The experiment was performed according to the pre-standardized protocol with minor modifications. 40 To evaluate the in vivo anti-tumor and anti-metastatic efficacy of 4DPG, healthy female Balb/c mice (25-30 g) were taken. Animals were randomized into two groups, and six animals were taken per group. For the tumor cells implantation, mouse mammary carcinoma 4T1 cells (1 × 10 6 per 200 μl) diluted in serum-free RPMI medium were injected subcutaneously into the mammary pad of each mouse around the second right mammary gland. A week after tumor cell implantation, when the palpable mammary tumors develop, mice were injected intraperitoneally with either vehicle (normal saline) or 4DPG (20 mg/kg/b.w.) in each alternative day for 2 weeks. Tumor sizes were measured in each alternate day after tumor cell injection, and the body weight was recorded once in a week. Mice were killed on the 15th day after treatment initiation, and tumors were dissected out carefully from the mammary pad area. Lungs were removed out, and lung metastatic nodules were photographed as well as quantified under a dissecting microscope. Lungs were then minced, treated with collagenase/DNase I solution for 2 h at 37°C and passed through the 70 μm cell strainer (BD) to obtain the single-cell suspension. The suspension was then diluted three to four times, resuspended in selection medium containing 6-thioguanine and further incubated for 15 days to isolate the 4T1 colonies. Colonies were then washed with PBS, fixed with methanol and stained with 0.2 % crystal violet solution and quantified under an inverted microscope.
Immunohistochemistry. For immunohistochemical detection, paraffinembedded tissue sections of the tumors (4DPG treated and untreated) were prepared. After dewaxination and hydration, tissue sections were subjected to endogenous peroxide blocking with 3% hydrogen peroxide in peroxidase blocking solution for 25 min. Antigen retrieval was done with citrate buffer (1 × ) for 25 min and then blocked for 1 h with 1% BSA. Sections were then incubated with primary antibodies for phospho-Chk2, total Chk2 and Twist1 (dilution 1:150), overnight at 4°C, then extensively washed with PBS and further incubated with HRP-conjugated secondary antibody (anti-rabbit) for 1 h at room temperature. Sections were exposed to 3,3′-diaminobenzidine (DAB) substrate, counterstained with Gill's hematoxylin no. 1 and finally dehydrated and mounted. Microscopic observation was carried out with the help of Zeiss fluorescence microscope Axioimager.Z2 (Carl Zeiss Light Microscopy, Jena, Germany).
Statistical analysis. Data were expressed as the mean ± S.D. of three independent experiments performed and analyzed by Student's t-test. IC 50 values were determined with the help of GraphPad Prism software Version 5.0 (GraphPad
